KRAS inhibitors, approved

Nat Cancer. 2021 Dec;2(12):1254-1256. doi: 10.1038/s43018-021-00289-3.

Authors

Rafael Rosell^{1

2

3}, Andrés Aguilar⁴, Carlos Pedraz⁵, Imane Chaib⁵

Affiliations

¹ Catalan Institute of Oncology, Badalona, Spain. rrosell@iconcologia.net.
² Oncology Institute Dr Rosell, IOR, Barcelona, Spain. rrosell@iconcologia.net.
³ Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. rrosell@iconcologia.net.
⁴ Oncology Institute Dr Rosell, IOR, Barcelona, Spain.
⁵ Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.

PMID: 35121930
DOI: 10.1038/s43018-021-00289-3

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Proto-Oncogene Proteins p21(ras)* / antagonists & inhibitors

Substances

Antineoplastic Agents
KRAS protein, human
Proto-Oncogene Proteins p21(ras)